Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500706 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
A Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,108
- Enrollment target
- 20
- Study locations
NCT02500706: Completed Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S.
NCT02500706 is a Phase 3 study of Diabetes and Diabetes Mellitus, Type 1 that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,108 participants, below the 3,025-participant average among 338 other Diabetes trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02500706, a Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,108 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted in Asia, Europe and North America. The purpose is to confirm efficacy in terms of glycaemic control of treatment with mealtime faster-acting insulin aspart in combination with insulin degludec in adults with Type 1 Diabetes Mellitus.
Primary Outcome
Change from baseline (week 0) in HbA1c was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related subject-site contact.
Conditions Studied
Interventions
- DRUG insulin aspart
- DRUG Faster-acting insulin aspart
- DRUG insulin degludec
Study Locations (20)
California
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Encino
- Novo Nordisk Investigational Site - Escondido
- Novo Nordisk Investigational Site - Fresno
- Novo Nordisk Investigational Site - Fullerton
- Novo Nordisk Investigational Site - Huntington Beach
- Novo Nordisk Investigational Site - Monterey
- Novo Nordisk Investigational Site - Newport Beach
- Novo Nordisk Investigational Site - Santa Barbara
- Novo Nordisk Investigational Site - Walnut Creek
Colorado
- Novo Nordisk Investigational Site - Denver
- Novo Nordisk Investigational Site - Golden
Florida
- Novo Nordisk Investigational Site - Palm Harbor
- Novo Nordisk Investigational Site - Tampa
Kentucky
- Novo Nordisk Investigational Site - Lexington
- Novo Nordisk Investigational Site - Louisville
Arizona
- Novo Nordisk Investigational Site - Tucson
Georgia
- Novo Nordisk Investigational Site - Roswell
Idaho
- Novo Nordisk Investigational Site - Idaho Falls
Kansas
- Novo Nordisk Investigational Site - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,108 participants |
| Start Date | 2016-05-04 |
| Est. Completion | 2017-08-16 |
| Phase | Phase 3 |
What the finished NCT02500706 record still lists
NCT02500706 is an interventional study that assigns participants to a tested intervention. Its 1,108 participants enrollment target places it among the larger protocols in the corpus, below the 3,025-participant average among 338 other Diabetes trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 3 interventions - of which insulin aspart is the first listed.
NCT02500706 names 20 study sites across 8 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT02500706 about?
NCT02500706 is a clinical study titled "Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes". This trial is conducted in Asia, Europe and North America. The purpose is to confirm efficacy in terms of glycaemic control of treatment with mealtime faster-acting insulin aspart in combination with insulin degludec in adults with Type 1 Diabetes Mellitus.
What is the current status of trial NCT02500706?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,108 participants. The study started on 2016-05-04. Estimated completion is 2017-08-16.
What conditions does trial NCT02500706 study?
This clinical trial studies the following conditions: Diabetes, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT02500706?
The interventions under investigation include: insulin aspart (DRUG), Faster-acting insulin aspart (DRUG), insulin degludec (DRUG).
Who is sponsoring clinical trial NCT02500706?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02500706 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02500706's enrollment target sits among peer trials
1,108 40th of 338 higher than 299 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial to Assess Chelation Therapy in Critical Limb Ischemia
RECRUITING · Phase 3
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
COMPLETED · Phase 3
-
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
COMPLETED · Phase 3
-
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
COMPLETED · Phase 3
-
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI